Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial
Not available.
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2024-11-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/11846 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846150487586373632 |
|---|---|
| author | Morag Griffin Shreyans Gandhi Richard J. Kelly Talha Munir Roochi Trikha Eden Hicks Deepak Jain Masayo Ogawa Ji Yu Petra Muus Austin G. Kulasekararaj |
| author_facet | Morag Griffin Shreyans Gandhi Richard J. Kelly Talha Munir Roochi Trikha Eden Hicks Deepak Jain Masayo Ogawa Ji Yu Petra Muus Austin G. Kulasekararaj |
| author_sort | Morag Griffin |
| collection | DOAJ |
| description |
Not available.
|
| format | Article |
| id | doaj-art-bf9d9c4e9ebe48db8d6a619467f89d7d |
| institution | Kabale University |
| issn | 0390-6078 1592-8721 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Ferrata Storti Foundation |
| record_format | Article |
| series | Haematologica |
| spelling | doaj-art-bf9d9c4e9ebe48db8d6a619467f89d7d2024-11-28T19:42:44ZengFerrata Storti FoundationHaematologica0390-60781592-87212024-11-01999110.3324/haematol.2024.285553Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trialMorag Griffin0Shreyans Gandhi1Richard J. Kelly2Talha Munir3Roochi Trikha4Eden Hicks5Deepak Jain6Masayo Ogawa7Ji Yu8Petra Muus9Austin G. Kulasekararaj10St James’s University Hospital, Leeds Teaching Hospitals NHS Trust, LeedsKing’s College Hospital, National Institute for Health and Care Research (NIHR) Wellcome Trust King’s Clinical Research Facility, LondonSt James’s University Hospital, Leeds Teaching Hospitals NHS Trust, LeedsSt James’s University Hospital, Leeds Teaching Hospitals NHS Trust, LeedsKing’s College Hospital, National Institute for Health and Care Research (NIHR) Wellcome Trust King’s Clinical Research Facility, LondonAlexion, AstraZeneca Rare Disease, Boston, MAAlexion, AstraZeneca Rare Disease, Boston, MAAlexion, AstraZeneca Rare Disease, Boston, MAAlexion, AstraZeneca Rare Disease, Boston, MASt James’s University Hospital, Leeds Teaching Hospitals NHS Trust, LeedsKing’s College Hospital, National Institute for Health and Care Research (NIHR) Wellcome Trust King’s Clinical Research Facility, London, UK; King’s College London, London Not available. https://haematologica.org/article/view/11846 |
| spellingShingle | Morag Griffin Shreyans Gandhi Richard J. Kelly Talha Munir Roochi Trikha Eden Hicks Deepak Jain Masayo Ogawa Ji Yu Petra Muus Austin G. Kulasekararaj Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial Haematologica |
| title | Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial |
| title_full | Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial |
| title_fullStr | Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial |
| title_full_unstemmed | Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial |
| title_short | Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial |
| title_sort | terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high dose eculizumab to ravulizumab a phase iv single arm clinical trial |
| url | https://haematologica.org/article/view/11846 |
| work_keys_str_mv | AT moraggriffin terminalcomplementinhibitionandcontrolofhemolysisinpatientswithparoxysmalnocturnalhemoglobinuriawhoswitchedfromhighdoseeculizumabtoravulizumabaphaseivsinglearmclinicaltrial AT shreyansgandhi terminalcomplementinhibitionandcontrolofhemolysisinpatientswithparoxysmalnocturnalhemoglobinuriawhoswitchedfromhighdoseeculizumabtoravulizumabaphaseivsinglearmclinicaltrial AT richardjkelly terminalcomplementinhibitionandcontrolofhemolysisinpatientswithparoxysmalnocturnalhemoglobinuriawhoswitchedfromhighdoseeculizumabtoravulizumabaphaseivsinglearmclinicaltrial AT talhamunir terminalcomplementinhibitionandcontrolofhemolysisinpatientswithparoxysmalnocturnalhemoglobinuriawhoswitchedfromhighdoseeculizumabtoravulizumabaphaseivsinglearmclinicaltrial AT roochitrikha terminalcomplementinhibitionandcontrolofhemolysisinpatientswithparoxysmalnocturnalhemoglobinuriawhoswitchedfromhighdoseeculizumabtoravulizumabaphaseivsinglearmclinicaltrial AT edenhicks terminalcomplementinhibitionandcontrolofhemolysisinpatientswithparoxysmalnocturnalhemoglobinuriawhoswitchedfromhighdoseeculizumabtoravulizumabaphaseivsinglearmclinicaltrial AT deepakjain terminalcomplementinhibitionandcontrolofhemolysisinpatientswithparoxysmalnocturnalhemoglobinuriawhoswitchedfromhighdoseeculizumabtoravulizumabaphaseivsinglearmclinicaltrial AT masayoogawa terminalcomplementinhibitionandcontrolofhemolysisinpatientswithparoxysmalnocturnalhemoglobinuriawhoswitchedfromhighdoseeculizumabtoravulizumabaphaseivsinglearmclinicaltrial AT jiyu terminalcomplementinhibitionandcontrolofhemolysisinpatientswithparoxysmalnocturnalhemoglobinuriawhoswitchedfromhighdoseeculizumabtoravulizumabaphaseivsinglearmclinicaltrial AT petramuus terminalcomplementinhibitionandcontrolofhemolysisinpatientswithparoxysmalnocturnalhemoglobinuriawhoswitchedfromhighdoseeculizumabtoravulizumabaphaseivsinglearmclinicaltrial AT austingkulasekararaj terminalcomplementinhibitionandcontrolofhemolysisinpatientswithparoxysmalnocturnalhemoglobinuriawhoswitchedfromhighdoseeculizumabtoravulizumabaphaseivsinglearmclinicaltrial |